CD69 and neoplasm: Compared to baseline, there was increased tumor infiltration following ipilimumab by fully activated (CD69+) CD3+/CD4+ T cells (mean change = 19; SD = 14, p = 0.06) and CD3+/CD8+ T cells (mean change = 11; SD = 19; p = 0.2).